Glucosamine sulfate, Chondroitin sulfate
"GAG for osteoarthritis of the knee--a prospective study"
Debi R; Robinson D; Agar G; Halperin N; Harefuah 2000 Mar 15;138(6):451-3,
Osteoarthritis results from progressive catabolic loss of cartilage
proteoglycans due to imbalance between synthesis and degradation. The
availability of glucosamine, an intermediate in mucopolysaccharide synthesis,
can be rate-limiting for proteoglycan production in cartilage tissue culture.
57 patients suffering from osteoarthritis of the knee were randomized
into a group treated for 4 weeks with daily i.v. glucosamine sulfate (GS)
together with 800 mg chondroitin sulfate, and a placebo group. Knee pain
at rest, on movement and on palpation, as well as range of knee motion
were then recorded.
In the GS group, there was significant reduction of clinical
symptoms (p < 0.01), but no significant reduction in the placebo
group. Physicians' assessment of tenderness and range of motion were significantly
in favor of the GS group (p < 0.01). In those treated with glycosamine
there were no adverse reactions and no changes in laboratory blood tests.
We conclude that GS can be considered the drug of choice for prolonged
treatment of osteoarthritis.